Pre-made Ozoralizumab benchmark antibody ( Bispecific Single Domains (VH-VH'-VH), anti-TNFA;ALB therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-419
Anti-TNFA;ALB therapeutic antibody (Pre-made Ozoralizumab biosimilar,Bispecific Single Domains (VH-VH'-VH)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFA;ALB therapeutic antibody (Pre-made Ozoralizumab biosimilar,Bispecific Single Domains (VH-VH'-VH))|
|Format||Bispecific Single Domains (VH-VH'-VH)|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||5m2j:D;None|
|Conditions Active||Rheumatoid arthritis|
|Conditions Discontinued||Ankylosing spondylitis;Crohn's disease;Psoriatic arthritis|
|Development Tech||Nanobody Technology|